Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

GE HealthCare and Mayo Clinic announced a novel theranostics study to explore a personalized approach to radioligand therapy for advanced prostate cancer.

The FDA has approved pegfilgrastim-pccg, a pegfilgrastim biosimilar, to decrease the incidence of infection in non-myeloid malignancies.

The FDA has approved pembrolizumab plus enfortumab vedotin in MIBC.

Risvutatug rezetecan met the primary OS end point of the phase 3 ARTEMIS-008 trial in Chinese patients with relapsed small-cell lung cancer.

The FDA approved subcutaneous isatuximab delivered via an on-body injector for multiple myeloma.

A real-world claims analysis linked zanubrutinib to improved time to next treatment and overall survival vs acalabrutinib in relapsed/refractory MCL.

Read a refresh of breast cancer FDA news from June 2026, including several practice-changing approvals and the granting of priority review to a SERD.